liafensine
Liafensine (BMS-820836) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) which was under development by Bristol-Myers Squibb for the treatment of major depressive disorder. Though it demonstrated comparable effectiveness to escitalopram and duloxetine in phase II clinical trials, development was paused in 2013 because liafensine failed to show superior effectiveness relative to these drugs, a decision that was made likely based on its increased capacity for side effects as well as potential for abuse. Another clinical trial of liafensine began in 2022. — Wikipedia
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Earliest trial started Jul 1, 2008 (NCT00964912)
Timeline
Indications
Mechanism of action
- Monoamine transporterINHIBITOR
Monoamine transporter inhibitor
Selectively inhibits the reuptake of serotonin, norepinephrine, and dopamine
Chemistry & pharmacology
SMILES
CN1Cc2cc(-c3ccc(N)nn3)ccc2[C@H](c2ccc3ccccc3c2)C1- Mol. weight
- 366.47 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaLiafensine ↗
- ChEMBLCHEMBL2364614 ↗
Also known as
- 6-(2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)pyridazin-3-amine
- bms-820836
- bms-820836
- bms-820836
- bms-820836
- liafensine
- liafensine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05113771 | Phase 2 | Mar 31, 2022 | Denovo BioPharma |
| NCT01396252 | Phase 1 | Sep 1, 2011 | Bristol-Myers Squibb |
| NCT01361555 | Phase 2 | Aug 1, 2011 | Bristol-Myers Squibb |
| NCT01369095 | Phase 2 | Jul 1, 2011 | Bristol-Myers Squibb |
| NCT01309945 | Phase 2 | Apr 1, 2011 | Bristol-Myers Squibb |
| NCT00892840 | Phase 1 | May 1, 2009 | Bristol-Myers Squibb |
| NCT00964912 | Phase 1 | Jul 1, 2008 | Bristol-Myers Squibb |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 6 | 6 | 2 | 2008 |
| Denovo BioPharma | For profit | 1 | 1 | 1 | 2022 |